News surrounding biosimilars referencing Humira (adalimumab) topped the list of biosimilar articles related to rheumatology in 2022, highlighting the excitement for these biosimilars to launch starting in early 2023.
News surrounding biosimilars referencing Humira (adalimumab) topped the list of biosimilar articles related to rheumatology in 2022, highlighting the excitement for these biosimilars to launch in the United States starting in early 2023.
5. FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar
The FDA approved the high-concentration version of Hadlima, 1 of 8 adalimumab biosimilars slated to launch on the US market next year. Hadlima was developed by Samsung Bioepis through a commercialization agreement with Organon, which will market the drug. The biosimilar is one of the only adalimumab biosimilars that will be offered in a high-concentration and a low-concentration formulation. Currently, the high-concentration version of the originator makes up about 80% of all adalimumab prescriptions.
To read the full article, click here.
4. Samsung Bioepis and Organon Seek to Enter the Market for High-Concentration Adalimumab
In January 2022, Samsung Bioepis and Organon, a spinoff of Merck, announced that they would collaborate to bring a high-concentration adalimumab biosimilar (Hadlima) to the US market. The product is expected to launch in July 2023 along with at least 6 others. The low-concentration version of Hadlima was approved in 2019. High-concentration adalimumab allows patients to receive fewer doses of adalimumab compared with a low-concentration version. The citrate-free aspect reduces pain for patients undergoing adalimumab therapy.
To read the full article, click here.
3. FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira
The FDA accepted biologics license applications (BLAs) from Alvotech and Pfizer requesting for their respective adalimumab biosimilars to have interchangeability designations in the United States. The FDA set a goal decision date of December 2022 and both biosimilars (AVT02 and Abrilada) are expected to launch in July 2023. Pfizer’s Abrilada was approved in November 2019 and Alvotech’s AVT02 is being reviewed by the FDA.
To read the full article, click here.
2. AbbVie Settles ITC Case With Alvotech; Humira Biosimilar to Launch July 2023
AbbVie settled its outstanding lawsuits, including a case related to the International Trade Commission (ITC), with Alvotech, allowing Alvotech to launch its high-concentration, citrate-free adalimumab biosimilar in July 2023 once it’s approved. The settlement fully resolved all pending US disputes between the companies. In the ITC case, AbbVie alleged that Alvotech developed AVT02 through theft of trade secrets. The agreement removed any remaining litigation barriers keeping AVT02 from launching on the US market.
To read the full article, click here.
1. Canada Clears Alvotech Adalimumab Biosimilar for Launch
Health Canada approved Alvotech’s adalimumab biosimilar for launch on the Canadian market, where it will be marketed as Simlandi. The approval granted Alvotech permission to launch the product immediately. Humira generated over $700 million in 2020 for AbbVie. Simlandi is available as a 40-mg/0.4-mL and 80-mg/0.8-mL doses in prefilled syringes and self-injector pens. The news came shortly after Celltrion Healthcare received approval or its adalimumab biosimilar (Yuflyma) in January 2022.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Meta-Analysis Confirms Similar Safety, Efficacy Between Adalimumab Biosimilars, Humira
April 6th 2024A systematic review and meta-analysis of 7 randomized controlled trials found no significant differences in efficacy and safety indicators between adalimumab biosimilars and the reference product (Humira) for treatment of moderate to severe psoriasis.